Business
Notice of AGM and posting of Annual Report
Notice of AGM and posting of Annual Report.
About this update from Genincode Plc
[{"type":"text","content":"\n\nGENinCode Plc\n(\"GENinCode\" or the \"Company\")\n \nPosting of Annual Report to Shareholders and Notice of Annual General Meeting\n \nOxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, confirms that the Annual Report and Accounts for the year ended 31 December 2022 and the Notice of Annual General Meeting (\"AGM\") have been posted to shareholders.\n \nA copy of the 2022 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy is now available to download from the Company website in accordance with AIM Rule 20:\n \nhttps://investors.genincode.com/investors\n \nThe AGM will be held in person at the offices of Cenkos Securities plc, 6,7,8 Tokenhouse Yard, London EC2R 7AS on Friday, 30 June 2023 at 2.00 p.m.\n \nFor more information visit www.genincode.com\n \nEnquiries:\n \n\n\n\nGENinCode Plc\n\n\nwww.genincode.com or via Walbrook PR\n\n\n\n\nMatthew Walls, CEO\n\n\n\n\n\n\n\nPaul Foulger, CFO\n \n\n\n\n\nStifel Nicolaus Europe Limited (Nomad and Joint Broker)\n\n\nTel: +44 (0)20 7710 7600\n\n\n\n\nAlex Price / Ben Maddison / Richard Short\n\n\n\n\n \nCenkos Securities Plc (Joint Broker)\n\n\n \nTel: +44 (0)20 7397 8900\n\n\n\n\nGiles Balleny\n\n\n\n\nDale Bellis / Michael Johnson (Sales)\n\n\n\n\n \nWalbrook PR Limited\nAnna Dunphy / Louis Ashe-Jepson / Phillip Marriage\n\n\n \nTel: 020 7933 8780 or [email protected] \n\n\n\n\n\n\n\n\n\n \nAbout GENinCode:\nGENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.\n \nGENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.\n \nGENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict the onset of cardiovascular disease.\n \nAbout Cardiovascular Disease (CVD):\n \nCVD is the leading cause of death globally, taking an estimated 17.9 million lives each year. ...